ProMIS to Showcase PMN310 at Five June Conferences Ahead of Q3 Data
PMN•ProMIS Neurosciences will present at five June 2026 conferences, including Jefferies, Wolfe R&D Day, Oppenheimer CNS Summit, H.C. Wainwright and BIO. The company will highlight its EpiSelect™ platform and PMN310 Alzheimer’s candidate, and expects blinded 6-month Phase 1b interim data in early Q3 2026, with 12-month topline in early 2027.
1. June Conference Participation
ProMIS will attend five conferences in June 2026, including Jefferies Global Healthcare Conference in New York (presentation June 4), Wolfe Research Alzheimer’s R&D Day (invitation-only presentation June 4), Oppenheimer CNS Summit in Miami (one-on-one meetings June 10), H.C. Wainwright Neuro Perspectives in New York (presentation June 15), and BIO International Convention in San Diego (one-on-one meetings June 22-25).
2. EpiSelect™ Platform and PMN310 Candidate
At each event, CEO Neil Warma will discuss the EpiSelect™ discovery engine and PMN310, a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers in Alzheimer’s disease while avoiding plaque binding to potentially reduce off-target effects.
3. Upcoming Clinical Data
ProMIS expects to report blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in early third quarter 2026, followed by 12-month topline results anticipated in early 2027.
